DHQ Hospital/Faisalabad Medical University, Faisalabad
Posters & Accepted Abstracts: Surgery Curr Res
Introduction: Latanoprost is a prostaglandin F2 alpha analog used in the treatment of glaucoma, found to induce skin pigmentation in guinea pigs in addition to its known periocular and iridal pigmentation side effects. Objective: The aim of this study is to compare the efficacy and safety of topical Latanoprost as an adjuvant for the treatment of vitiligo. Materials and Method: Ten patients with bilateral symmetrical vitiligo lesions were enrolled. Both sides were treated with the standard conventional treatment (narrowband UVB twice weekly plus topical 0.05% clobetasol propionate ointment twice a day for first 3 weeks alternating with topical tacrolimus twice a day for next 2 weeks). The right side was additionally treated with topical latanoprost twice a day for 12 weeks. Standard digital photographs of both sides were taken at baseline, monthly and at 12 weeks after starting treatment. Improvement of vitiligo was scored objectively by two blinded dermatologists using a quartile grading scale (Grade 0: no improvement, Grade1: 1-25% re-pigmentation, Grade2: 26-50%, Grade3: 51-75%, Grade4: >75% re-pigmentation). The patients were asked to grade their overall satisfaction using a 10-point visual analog scale (VAS) from 0 (not satisfied at all) to 10 (extremely satisfied). Adverse events and complications were recorded at every follow-up visit. Results: The study is ongoing but patients, who have completed the initial trial period, show statistically significant (p>0.5) improvement on the side where latanoprost was also performed. Conclusion: Latanoprost seems to be another good adjuvant to the standard medical treatment of Vitiligo but further randomized clinical trials with larger sample size are required to establish its definite role.